Characterization of the novel HLA-DRB1*11:01:01:12N allele by sequencing-based typing.

HLA-DRB1*11:01:01:12N HLA novel allele sequencing-based typing splice site

Journal

HLA
ISSN: 2059-2310
Titre abrégé: HLA
Pays: England
ID NLM: 101675570

Informations de publication

Date de publication:
12 2023
Historique:
revised: 10 08 2023
received: 07 08 2023
accepted: 13 08 2023
medline: 13 11 2023
pubmed: 22 8 2023
entrez: 22 8 2023
Statut: ppublish

Résumé

HLA-DRB1*11:01:01:12N differs from HLA-DRB1*11:01:01:03 by one nucleotide substitution in intron 3 at position c.652+1G>C, hg19.

Identifiants

pubmed: 37605385
doi: 10.1111/tan.15205
doi:

Substances chimiques

HLA-DRB1 Chains 0
Nucleotides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

765-768

Informations de copyright

© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Cargou M, Ralazamahaleo M, Blouin L, et al. Evaluation of the AllType kit for HLA typing using the ion torrent S5 XL platform. HLA. 2020;95(1):30-39. doi:10.1111/tan.13708
Barker DJ, Maccari G, Georgiou X, et al. The IPD-IMGT/HLA database. Nucleic Acids Res. 2023;51(D1):D1053-D1060. doi:10.1093/nar/gkac1011
Mayor NP, Robinson J, McWhinnie AJM, et al. HLA typing for the next generation. PloS One. 2015;10(5):e0127153. doi:10.1371/journal.pone.0127153
Visentin J, Bachelet T, Aubert O, et al. Reassessment of the clinical impact of preformed donor-specific anti-HLA-Cw antibodies in kidney transplantation. Am J Transplant. 2020;20(5):1365-1374. doi:10.1111/ajt.15766
Marsh SGE, Albert ED, Bodmer WF, et al. Nomenclature for factors of the HLA system, 2010. Tissue Antigens. 2010;75(4):291-455. doi:10.1111/j.1399-0039.2010.01466.x

Auteurs

Marine Cargou (M)

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.

Vincent Elsermans (V)

CHU de Lille, Institut d'Immunologie-HLA, Lille, France.

Charlotte A Cambridge (CA)

Anthony Nolan Research Institute, Royal Free Hospital, London, UK.

Eulalie Lasseaux (E)

CHU de Bordeaux, Laboratoire de Génétique Médicale, Hôpital Pellegrin, Bordeaux, France.

Jonathan Visentin (J)

CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.
Univ. Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH